Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase

International Journal of Hematology

Volumn 82, Issue 4, 2005, Pages 333-337

  Miyoshi, Natsuki ^a   Tanaka, Hideo ^a   Ito, Takuo ^a   Katayama, Yuta ^a   Niimi, Hiromasa ^a   Hyodo, Hideo ^a   Kimura, Akiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

CML; Hypercalcemia; Imatinib; Lyn; PTHrP

Indexed keywords

ALPHA INTERFERON; CALCITONIN; CALCIUM ION; CYTARABINE; CYTARABINE 5' STEARYLPHOSPHATE; DAUNORUBICIN; DIURETIC AGENT; ELCATONIN; ENOCITABINE; HYDROXYUREA; IDARUBICIN; IMATINIB; INCADRONIC ACID; MESSENGER RNA; METHYLPREDNISOLONE; PARATHYROID HORMONE RELATED PROTEIN; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGED; ARTICLE; BLAST CELL; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMORAL HYPERCALCEMIA OF MALIGNANCY; HYPERCALCEMIA; MONOTHERAPY; PANCYTOPENIA; PATHOGENESIS; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME; BLAST CELL CRISIS; BLOOD; BONE MARROW CELL; GENETICS; HYPERPLASIA; MUTATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; ANTINEOPLASTIC AGENTS; BLAST CRISIS; BONE MARROW CELLS; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPLASIA; LEUKEMIA, MYELOID, CHRONIC; MUTATION; PARATHYROID HORMONE-RELATED PROTEIN; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33644678901     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05063     Document Type: Article

References (24)

1. Firkin F, Schneider H, Grill V. Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy. Leuk Lymphoma. 1998;29:499-506.
2. Hibi S, Funaki H, Ochiai-Kanai R, et al. Hypercalcemia in children presenting with acute lymphoblastic leukemia. Int J Hematol. 1997;66:353-357.
3. Kounami S, Yoshiyama M, Nakayama K, Hiramatsu C, Aoyagi N, Yoshikawa N. Severe hypercalcemia in a child with acute nonlymphocytic leukemia: the role of parathyroid hormone-related protein and proinflammatory cytokines. Acta Haematol. 2004;112:160-163.
4. Vlasveld LT, Pauwels P, Ermens AA, Aarnoudse WH, Ooms HW, Haak HR. Parathyroid hormone-related protein (PTH-rP)-associated hypercalcemia in a patient with an atypical chronic lymphocytic leukemia. Neth J Med. 1999;54:21-26.
5. Shimonodan H, Nagayama J, Nagatoshi Y, et al. Acute lymphocytic leukemia in adolescence with multiple osteolytic lesions and hypercalcemia mediated by lymphoblast-producing parathyroid hormone-related peptide: a case report and review of the literature. Pediatr Blood Cancer. 2005;44:1-7.
6. Seymour JF, Grill V, Martin TJ, Lee N, Firkin F. Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein. Leukemia. 1993;7:1672-1675.
7. Sasaki Y, Takahashi T, Tsuyuoka R, et al. Hypercalcemia mediated by parathyroid hormone-related protein in chronic myeloid leukemia. Am J Hematol. 1994;47:251-252.
8. Watanabe T, Kataoka T, Mizuta S, et al. Establishment and characterization of a novel cell line, TK-6, derived from T cell blast crisis of chronic myelogenous leukemia, with the secretion of parathyroid hormone-related protein. Leukemia. 1995;9:1926-1934.
9. Kubonishi I, Asahi Y, Machida H, et al. PTHrP-mediated hypercalcaemia in a case of CML blast crisis. Br J Haematol. 1997;96:165-167.
10. Kwak HS, Sohn MH, Lim ST, Kwak JY, Yim CY. Technetium-99m MDP bone scintigraphic findings of hypercalcemia in accelerated phase of chronic myelogenous leukemia. J Korean Med Sci. 2000;15:598-600.
11. Kakihana K, Mizuchi D, Yamaguchi M, et al. Hypercalcemia mediated by parathyroid hormone-related protein in the blastic phase of chronic myelogenous leukemia [in Japanese]. Rinsho Ketsueki. 2002;43:102-106.
12. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.
13. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with Interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-858.
14. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human Interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986;314:1065-1069.
15. Li X, Drucker DJ. Parathyroid hormone-related peptide is a downstream target for ras and src activation. J Biol Chem. 1994;269:6263-6266.
16. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004;36:453-461.
17. Silver RT, Talpaz M, Sawyers CL, et al. Four year follow-up of phase II trials of patients with chronic myeloid leukemia (CML) treated with imatinib: patients with late chronic phase (CP), accelerated phase (AP), or myeloid blast crisis (BC). In: Program and abstracts of the 46th Annual Meeting of the American Society of Hematology; December 4-7, 2004; San Diego, California, USA. Abstract 23.
18. Motokura T, Endo K, Kumaki K, Ogata E, Ikeda K. Neoplastic transformation of normal rat embryo fibroblasts by a mutated p53 and an activated ras oncogene induces parathyroid hormone-related peptide gene expression and causes hypercalcemia in nude mice. J Biol Chem. 1995;270:30857-30861.
19. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010-4022.
20. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem. 2004;279:34227-34239.
21. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690-698.
22. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med. 2004;10:1187-1189.
23. Uchiumi F, Semba K, Yamanashi Y, et al. Characterization of the promoter region of the src family gene lyn and its trans activation by human T-cell leukemia virus type I-encoded p40tax. Mol Cell Biol. 1992;12:3784-3795.
24. Dittmer J, Pise-Masison CA, Clemens KE, Choi KS, Brady JN. Interaction of human T-cell lymphotropic virus type I Tax, Ets1, and Sp1 in transactivation of the PTHrP P2 promoter. J Biol Chem. 1997;272:4953-4958.